目的：探讨应用尿激酶静脉溶栓治疗不同时间段心肌梗死的疗效。方法：随机选取佛山市第五人民医院自2009年5月—2013年5月收治的45例心肌梗死患者，均采用尿激酶静脉溶栓治疗，回顾性对比分析所有患者的临床疗效。结果：45例急性心肌梗死患者中，有34例患者达到冠状动脉再通标准，冠状动脉再通成功率为75.56％，11例未达到冠状动脉再通标准；其中发病后6 h内进行静脉溶栓治疗的冠状动脉再通率为82.35％（28／34），发病6～12 h内的冠状动脉再通率为54.55％（6／11），2组冠状动脉再通成功率的差异有统计学意义（P＜0.05），而2组患者发生并发症的差异无统计学意义（P＞0.05）。结论：尿激酶作为静脉溶栓治疗的常用药，对早期急性心肌梗死的临床疗效显著，且发病后越早应用，疗效越佳，同时治疗后并发症发生率较低，值得临床推广。%OBJECTIVE:To evaluate the efficacy of urokinase thrombolytic therapy( intravenously) for myocardial infarction at different time period.METHODS:45 patietns with myocardial infarction treated in our hospital from May 2009 to May 2013 were randomly selected to receive intravenous urokinase thrombolytic therapy, with clinical efficacy analyzed retrospectively.RESULTS:Of the 45 patients with acute myocardial infarction, recanalization was noted in 34(75.56%) but unnoted in 11 cases.Recanalization occurred in 82.35%(28/34) in those who received thrombolytic therapy within 6 hours'onset of disease versus 54.55%(6/11) in those who received thrombolytic therapy within 6-12 hours'onset of disease, showing statistically significant difference between the two groups ( P 0.05 ) . CONCLUSIONS:Urokinase thrombolytic therapy( intravenously) showed remarkable efficacy for myocardial infarction. The early use is associated with its better efficacy.Furthermore, it caused low incidence of complications, thus its use is worthy of clinical recommendation.
展开▼
